

# INTERNATIONAL SEARCH REPORT

International Application No

PCmP2004/013728

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/663 A61K31/337 A61K31/4196 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDSEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and where practical search terms used)

EPO-Internal , CHEM ABS Data, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category "	Citation of document, with indication, where appropriate of the relevant passages	Relevant to claim No
P, X	<p>ALGUR E ET AL: "Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines"</p> <p>INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol . 61, no. 2, 1 February 2005 (2005-02-01), pages 535-542, XP004749602 ISSN: 0360-3016 page 539, column 2, paragraph 1</p> <p>-/-</p>	<p>1-5, 7-11, 15, 16, 19-21, 23-26</p>

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex

### \* Special categories of cited documents

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"S" document member of the same patent family

Date of the actual completion of the international search

21 September 2005

Date of mailing of the international search report

12 a ID. 2005

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2  
NL- 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Skj øldebrand, C

# INTERNATIONAL SEARCH REPORT

International Application No

PCTWP2004/01 3728

## e.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	wo 03/035081 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; GREEN, JONATHAN; LIPTON, ALLAN; WIT) 1 May 2003 (2003-05-01 )  the whole document	1-5, 7-11 , 15, 16, 19-21 , 23-26
X	JAGDEV S P ET AL: "THE BISPHOSPHONATE, ZOLEDRONIC ACID, INDUCES APOPTOSIS OF BREAST CANCER CELLS: EVIDENCE FOR SYNERGY WITH PACLITAXEL" BRITISH JOURNAL OF CANCER, LONDON, GB, vol . 8, no. 84, 2001 , pages 1126-1134, XP008001603 ISSN : 0007-0920 abstract	1-5, 7-11 , 15, 16, 19-21 , 23-26
P, X	wo 2004/012728 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; BHATNAGAR, AJAY, S; EVANS, DEAN, BR) 12 February 2004 (2004-02-12)  the whole document	1-5, 7-10, 12, 15, 17, 19-21 , 23-26
X	KOKUFU I ET AL: "'A case of effective bisphosphonate therapy of sequential pamidronate and incadronate for bone metastases from breast cancer! " GAN TO KAGAKU RYOHO. CANCER & CHEMOTHERAPY. AUG 2000, vol . 27, no. 9, August 2000 (2000-08) , pages 1425-1428, XP002345936 ISSN: 0385-0684 abstract	1-5, 7-10, 12, 15, 17, 19-21 , 23-26
X	HARVEY H A: "ISSUES CONCERNING THE ROLE OF CHEMOTHERAPY AND HORMONAL THERAPY OF BONE METASTASES FROM BREAST CARCINOMA" CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol . 80, no. 8, SUPPL, 1997, pages 1646-1651 , XP000929334 ISSN: 0008-543X abstract	1-5, 7-10, 12, 15, 17, 19-21 , 23-26
X	HARVEY H A: "Therapeutic use of bisphosphonates in breast cancer: Studies with zoledronic acid" AMERICAN JOURNAL OF CANCER 2003 NEW ZEALAND, vol . 2, no. SUPPL. , 2003, pages 19-25, XP009054127 ISSN: 1175-6357 abstract	1-5, 7-10, 12, 15, 17, 19-21 , 23-26

-/--

# INTERNATIONAL SEARCH REPORT

International Application No  
PCTWP2004/013728

e.(Cofthi πuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>FREYER G ET AL: "Palliative hormone therapy, low dose chemotherapy and bisphosphonate in breast cancer patients with bone marrow involvement and pancytopenia; report of pilot experience" EUROPEAN JOURNAL OF INTERNAL MEDICINE, ELSEVIER, AMSTERDAM,, NL, vol. 11, 2000, pages 329-333, XP002257266 ISSN: 0953-6205 abstract</p> <p>-----</p>	<p>1-5, 7-10,12, 15,17, 19-21, 23-26</p>
X	<p>NEVILLE-WEBBE HL, EVANS CA, COLEMAN RE, HOLEN I: "THE COMBINATION OF ZOLEDRONIC ACID (ZOL) AND TRAIL (TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND) HAS POTENTIAL SYNERGISTIC ACTION IN BREAST CANCER CELLS (BCC)" CLINICAL ONCOLOGY, vol. 15, September 2003 (2003-09), pages S28-S29, XP009054117 abstract</p> <p>-----</p>	<p>1-4,6, 13-15, 18-20, 22-26</p>

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2004/013728

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons

- 1 ☒ Claims Nos  
because they relate to subject matter not required to be searched by this Authority, namely  
  
Although claims 7-17 and 21-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
- 2 ☐ Claims Nos  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out specifically
- 3 ☐ Claims Nos  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a)

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows

see additional sheet

- 1 ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims
- 2 ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee
- 3 ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos
- 4 ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims it is covered by claims Nos

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest
- ☒ No protest accompanied the payment of additional search fees

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-5, 7-11, 15-16, 19-21, 23-26 (in part)

Taxol and a bisphosphonate for sequential use in the treatment of malignancies .  
---

2. claims: 1-5, 7-10, 12, 15, 17, 19-21, 23-26 (in part)

An aromatase inhibitor and a bisphosphonate for sequential use in the treatment of malignancies .  
---

3. claims: 1-4, 6, 13-15, 18-20, 22-26 (in part)

TRAIL and a bisphosphonate for sequential use in the treatment of malignancies .  
---

BEST AVAILABLE COPY

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCTWP2004/013728

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
wo 03035081 A	01-05-2003	BR 0213410 A	03-11-2004
		CA 2461085 A1	01-05-2003
		EP 1443942 A1	11-08-2004
		HU 0402061 A2	28-02-2005
		JP 2005506371 T	03-03-2005
		NO 20042056 A	18-05-2004
wo 2004012728 A	12-02-2004	AU 2003250190 A1	23-02-2004
		BR 0313081 A	12-07-2005
		CA 2494345 A1	12-02-2004
		EP 1534265 A1	01-06-2005